| All (n = 72) | ASSD (n = 36) | IMNM (n = 8) | DM (n = 28) | Control (n = 67) | P value* | |
| Demographics |
|
|
|
|
|
|
| Age (years) | 48.1 ± 12.8 | 47.2 ± 14.9 | 53.6 ± 12.2 | 47.7 ± 11.7 | 46.2 ± 15.4 | 0.458 |
| Female (%) | 54 (75.0) | 25 (69.4) | 7 (87.5) | 22 (78.6) | 58 (86.6) | 0.092 |
| BMI (kg/m2) | 27.2 ± 6.4 | 27.9 ± 7.1 | 23.5 ± 6.1 | 27.3 ± 5.4 | 25.2 ± 3.7 | 0.197 |
| Disease status |
|
|
| |||
| Physician’ VAS (0 - 10) | 0.0 (0.0 - 0.0) | 0.0 (0.0 - 0.0) | 0.0 (0.0 - 0.0) | 0.0 (0.0 - 0.0) | - | - |
| Patient’s VAS (0 - 10) | 4.2 (0.0 - 6.5) | 3.0 (0.0 - 7.0) | 5.0 (2.5 - 5.7) | 5.0 (2.0 - 6.7) | - | - |
| HAQ (0.0 - 3.0) | 0.4 (0.0 - 1.2) | 0.3 (0.0 - 1.0) | 0.4 (0.0 - 1.8) | 0.7 (0.3 - 1.6) | - | - |
| MMT-8 (0 - 80) | 80 (80 - 80) | 80 (80 - 80) | 80 (80 - 80) | 80 (80 - 80) | - | - |
| Creatine phosphokinase (U/L) | 109 (67 - 201) | 116 (71 - 193) | 300 (54 - 594) | 94 (65 - 194) | - | - |
| Treatment |
|
|
| |||
| Prednisone (%) | 21 (29.2) | 7 (19.4) | 2 (25.0) | 12 (42.9) | - | - |
| Prednisone (mg/day) | 0.0 (0.0 - 5.0) | 0.0 (0.0 - 5.0) | 0.0 (0.0 - 15.0) | 0.0 (0.0 - 10.0) | - | - |
| Methotrexate (%) | 6 (8.3) | 2 (5.6) | 1 (12.5) | 3 (10.7) | - | - |
| Azathioprine (%) | 14 (19.4) | 5 (13.5) | 1 (12.5) | 8 (28.6) | - | - |
| Mycophenolate mofetil (%) | 14 (19.4) | 7 (19.4) | 3 (37.5) | 4 (14.3) | - | - |
| Other drugs |
|
|
| |||
| Anti-hypertensive (%) | 24 (33.3) | 9 (25.0) | 1 (12.5) | 14 (50.0) | - | - |
| Anti-depressants (%) | 4 (5.6) | 1 (2.8) | 0 | 3 (10.7) | - | - |
| Pain-relievers (%) | 13 (18.1) | 4 (11.1) | 1 (12.5) | 8 (28.6) | - | - |
| Lipid-lowering drugs (%) | 5 (6.9) | 3 (10.7) | 0 | 2 (5.6) | - | - |
| Comorbidities |
|
|
| |||
| Arterial hypertension (%) | 24 (33.3) | 9 (25.0) | 1 (12.5) | 14 (50.0) | - | - |
| Dyslipidemia (%) | 15 (20.8) | 8 (22.2) | 2 (25.0) | 5 (17.9) | - | - |
| Hypothyroidism (%) | 5 (6.9) | 3 (8.3) | 0 | 2 (7.1) | - | - |
| Diabetes mellitus (%) | 14 (19.4) | 4 (11.1) | 0 | 10 (35.7) | - | - |
| Depression (%) | 1 (1.4) | 0 | 0 | 1 (3.6) | - | - |
| Fibromyalgia (%) | 6 (8.3) | 3 (8.3) | 0 | 3 (10.7) | - | - |
| Pain perception (VAS) |
|
|
| |||
| Light (0.0 - 3.0) | 26 (36.1) | 18 (50.0) | 2 (25.0) | 6 (21.4) | 34 (50.7) |
|
| Moderate (4.0 - 8.0) | 29 (40.3) | 10 (27.8) | 5 (62.5) | 14 (50.0) | 26 (38.8) | 0.045 |
| Intense (8.0 - 10) | 17 (23.1) | 8 (22.2) | 1 (12.5) | 8 (28.6) | 7 (10.4) |
|
| Fatigue perception (VAS) |
|
|
| |||
| Mild (0.0 - 3.0) | 24 (33.3) | 16 (44.4) | 2 (25.0) | 8 (21.4) | 20 (29.9) |
|
| Moderate (4.0 - 8.0) | 27 (37.5) | 10 (27.8) | 3 (37.5) | 14 (50.0) | 30 (44.8) | 0.702 |
| Intense (8.0 - 10) | 21 (29.2) | 10 (27.8) | 3 (37.5) | 8 (28.6) | 17 (25.4) |
|
| Fatigue severity |
|
|
| |||
| FSS (0.0 - 7.0) | 4.0 ± 2.1 | 3.4 ± 1.8 | 3.5 ± 0.4 | 4.9 ± 0.7 | 3.6 ± 1.5 | 0.726 |
| Physical activity levels |
|
|
| |||
| Low | 52 (72.2) | 26 (72.2) | 7 (87.5) | 19 (67.9) | 37 (56.1) |
|
| Moderate | 16 (22.2) | 8 (22.2) | 1 (12.5) | 7 (25.0) | 14 (21.2) | 0.053 |
| High | 4 (5.6) | 2 (5.6) | 0 | 2 (7.1) | 15 (22.7) |
|